SCHEMBL2359345

SCHEMBL2359345

O=C(O)NC(CCCO)c1ccccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 3/20 0.46
HTT P42858 1/20 0.42
CCR3 P51677 1/20 0.36
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
GLS O94925 1/20 0.34
ALDH1A1 P00352 3/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MMP1 P03956 2/20 0.32
MMP3 P08254 2/20 0.32
MMP8 P22894 2/20 0.32
LMNA P02545 1/20 0.32
NLRP3 Q96P20 1/20 0.32
CTSA P10619 1/20 0.32
HPGD P15428 1/20 0.32
PRKACA P17612 1/20 0.32
CDK8 P49336 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325177 0.80 CTSK (0.44) CYP26A1HTT
SCHEMBL2325180 0.80 CTSK (0.44) CYP26A1HTT
SCHEMBL17846092 0.79 CCR3 (0.50) HTTCCR3ALDH1A1SMN1; SMN2LMNA
SCHEMBL27821871 0.78 CTSK (0.43) HTTCYP2C19ALDH1A1SMN1; SMN2LMNA
SCHEMBL2321113 0.76 CYP26A1 (0.43) CYP26A1HTTCYP2C19CYP2C9ALDH1A1
SCHEMBL17846187 0.74 CCR3 (0.49) HTTCCR3ALDH1A1SMN1; SMN2LMNA
SCHEMBL17440495 0.72 ALDH1A1 (0.39) CCR3ALDH1A1LMNACTSAHPGD
SCHEMBL9899776 0.72 IDO1 (0.42) HTTCYP2C19ALDH1A1CYP3A4ALOX15
SCHEMBL3447746 0.72 CNR2 (0.48) GAACTSAPRKACACDK8GSK3A
SCHEMBL27620574 0.72 HTT (0.46) CYP26A1HTTCYP2C19CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356105-B1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN MSD OSS BV (NL) 2013-04-10 EP disclosed
US-8188123-B2 (Pyrrolidin-2-yl)phenyl derivatives MERCK SHARP & DOHME B.V. (NL) 2012-05-29 US disclosed
EP-2356105-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. Organon (NL) 2011-08-17 EP disclosed
WO-2010052198-A1 ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN N.V. ORGANON (NL) 2010-05-14 WO disclosed
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES N.V. ORGANON 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113493-A1 (PYRROLIDIN-2-YL)PHENYL DERIVATIVES CNR1, CNR2, TRPV1 CYP26A1 2454/4885HTT 123/4885CCR3 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.